Skip to main content

Table 3 Description of non-serious adverse events

From: Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial

  Ivermectin (N = 250) Placebo (N = 251)
Non-serious adverse event, N (%) 45 (18) 53 (21.11)
Perianal abscess, N (%) 0 (0) 1 (0.4)
Anosmia, N (%) 3 (1.2) 1 (0.4)
Asthenia, N (%) 0 (0) 1 (0.4)
Headache, N (%) 1 (0.4) 5 (2)
Diarrhea, N (%) 6 (2.4) 8 (3.2)
Dysgeusia, N (%) 1 (0.4) 0 (0)
Dyspnea, N (%) 1 (0.4) 3 (1.2)
Back pain, N (%) 0 (0) 1 (0.4)
Chest pain, N (%) 1 (0.4) 0 (0)
Worsening muscle pain, N (%) 1 (0.4) 0 (0)
Epistaxis, N (%) 0 (0) 1 (0.4)
Fatigue, N (%) 0 (0) 1 (0.4)
Fever, N (%) 4 (1.6) 4 (1.6)
Stomach flu, N (%) 0 (0) 1 (0.4)
Dizziness, N (%) 1 (0.4) 0 (0)
Myalgia, N (%) 3 (1.2) 0 (0)
Nauseas, N (%) 1 (0.4) 4 (1.6)
Pneumonia, N (%) 16 (6.4) 8 (3.2)
Odynophagia, N (%) 0 (0) 1 (0.4)
Palpitations, N (%) 1 (0.4) 0 (0)
Rash, N (%) 0 (0) 2 (0.8)
Dry cough, N (%) 0 (0) 7 (2.8)
Urticaria, N (%) 1 (0.4) 2 (0.8)
Vomiting, N (%) 0 (0) 1 (0.4)
Arthralgia, N (%) 1 (0.4) 0 (0)
Sciatica, N (%) 0 (0) 1 (0.4)
Progression of dyspnea, N (%) 1 (0.4) 0 (0)
Abdominal pain, N (%) 1 (0.4) 0 (0)
Foot trauma, N (%) 1 (0.4) 0 (0)